BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23735723)

  • 1. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Althouse AD; Abbott JD; Sutton-Tyrrell K; Forker AD; Lombardero MS; Buitrón LV; Pena-Sing I; Tardif JC; Brooks MM;
    Diabetes Care; 2013 Oct; 36(10):3269-75. PubMed ID: 23735723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for incident peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D) Trial.
    Althouse AD; Abbott JD; Forker AD; Bertolet M; Barinas-Mitchell E; Thurston RC; Mulukutla S; Aboyans V; Brooks MM;
    Diabetes Care; 2014; 37(5):1346-52. PubMed ID: 24595631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort.
    Pop-Busui R; Lu J; Brooks MM; Albert S; Althouse AD; Escobedo J; Green J; Palumbo P; Perkins BA; Whitehouse F; Jones TL;
    Diabetes Care; 2013 Oct; 36(10):3208-15. PubMed ID: 23757426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Hazard of Myocardial Infarction With Insulin-Provision Therapy in Actively Smoking Patients With Diabetes Mellitus and Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial.
    Khan AA; Chung MJ; Novak E; Brown DL
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28903941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.
    Chaitman BR; Hardison RM; Adler D; Gebhart S; Grogan M; Ocampo S; Sopko G; Ramires JA; Schneider D; Frye RL;
    Circulation; 2009 Dec; 120(25):2529-40. PubMed ID: 19920001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from BARI-2D trial.
    Damluji AA; Cohen ER; Moscucci M; Myerburg RJ; Cohen MG; Brooks MM; Rich MW; Forman DE
    Int J Cardiol; 2017 Aug; 241():35-40. PubMed ID: 28314486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis.
    Ismail-Beigi F; Lombardero MS; Escobedo J; Genuth S; Green J; Massaro E; Mooradian AD; Ovalle F; Whitehouse F; Zonszein J;
    J Diabetes Complications; 2014; 28(1):101-9. PubMed ID: 23478173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes).
    Chung SC; Hlatky MA; Faxon D; Ramanathan K; Adler D; Mooradian A; Rihal C; Stone RA; Bromberger JT; Kelsey SF; Brooks MM;
    J Am Coll Cardiol; 2011 Aug; 58(8):810-9. PubMed ID: 21835316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group
    Am Heart J; 2008 Sep; 156(3):528-536, 536.e1-5. PubMed ID: 18760137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BARI 2D: A Reanalysis Focusing on Cardiovascular Events.
    Genuth SM; Vlachos H; Brooks MM; Bantle JP; Chaitman BR; Green J; Kelsey SF; King SB; McBane R; Sako EY; Schneider DJ; Steffes M; Frye RL;
    Mayo Clin Proc; 2019 Nov; 94(11):2249-2262. PubMed ID: 31590967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial.
    Wolk R; Bertolet M; Brooks MM; Pratley RE; Sobel BE; Frye RL; Singh P; Calvin AD; Rutter MK; Mooradian AD; Somers VK;
    Eur J Prev Cardiol; 2016 Jan; 23(1):50-8. PubMed ID: 25073857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial.
    Hlatky MA; Boothroyd DB; Melsop KA; Kennedy L; Rihal C; Rogers WJ; Venkitachalam L; Brooks MM;
    Circulation; 2009 Dec; 120(25):2550-8. PubMed ID: 19920002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: a report from the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes).
    Tamis-Holland JE; Lu J; Korytkowski M; Magee M; Rogers WJ; Lopes N; Mighton L; Jacobs AK;
    J Am Coll Cardiol; 2013 Apr; 61(17):1767-76. PubMed ID: 23500245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort.
    Pop-Busui R; Lu J; Lopes N; Jones TL;
    J Peripher Nerv Syst; 2009 Mar; 14(1):1-13. PubMed ID: 19335534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Sobel BE; Hardison RM; Genuth S; Brooks MM; McBane RD; Schneider DJ; Pratley RE; Huber K; Wolk R; Krishnaswami A; Frye RL;
    Circulation; 2011 Aug; 124(6):695-703. PubMed ID: 21768545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease.
    Pallisgaard JL; Brooks MM; Chaitman BR; Boothroyd DB; Perez M; Hlatky MA;
    Am J Med; 2018 Jul; 131(7):805-812. PubMed ID: 29581079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study).
    Pop-Busui R; Lombardero M; Lavis V; Forker A; Green J; Korytkowski M; Sobel BE; Jones TL;
    Am J Cardiol; 2009 Jul; 104(1):52-8. PubMed ID: 19576321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BARI 2D study: a randomised trial of therapies for type 2 diabetes and coronary artery disease.
    Rutter MK; Nesto RW
    Diab Vasc Dis Res; 2010 Jan; 7(1):69-72. PubMed ID: 20368235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for glycemic control in nonobese and obese type 2 diabetic patients with coronary artery disease.
    Tsujimoto T; Kajio H
    Int J Cardiol; 2019 May; 282():1-6. PubMed ID: 30772014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
    Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
    Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.